generic versions of a groundbreaking injectable drug to prevent HIV

The two organisations have entered into separate agreements with Indian pharmaceutical companies to produce cheaper generic versions of lenacapavir – a twice-yearly injection shown to reduce the risk of HIV transmission by more than 99.9 percent – for [more than 100] low- and middle-income countries.

Marketed under the brand name Yeztugo by California-based Gilead Sciences, lenacapavir currently costs around $28,000 a year in the United States.